SCHEMBL8399137

SCHEMBL8399137

CCN(CC)CCCOC(=O)OCCCN(CC)CC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.47
CHRM4 P08173 3/20 0.47
CHRM1 P11229 3/20 0.47
CHRM3 P20309 3/20 0.47
SCN1A P35498 3/20 0.47
SCN2A Q99250 3/20 0.47
SCN3A Q9NY46 3/20 0.47
CYP2D6 P10635 4/20 0.45
CYP3A4 P08684 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HTR1A P08908 2/20 0.45
DRD3 P35462 2/20 0.45
SLC6A3 Q01959 2/20 0.45
BCHE P06276 1/20 0.45
CHRM5 P08912 1/20 0.45
ADRA2C P18825 1/20 0.45
HRH2 P25021 1/20 0.45
HTR1D P28221 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16154785 0.94 ALDH1A1 (0.52) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL16844981 0.94 CHRM2 (0.44) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL8557336 0.91 CYP2D6 (0.51) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL16844980 0.90 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL24562876 0.88 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3SCN1A
Hydrochloric Acid SCHEMBL8396381 0.88 MEN1 (0.51) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL18195644 0.87 CYP2D6 (0.42) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL21413020 0.87 SLC22A1 (0.49) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL24763399 0.87 CHRM2 (0.40) CHRM2CHRM4CHRM1CHRM3SCN1A
SCHEMBL7058546 0.86 LMNA (0.50) CHRM2CHRM4CHRM1CHRM3SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3188760-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2023-12-06 EP claimed
US-10844002-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-11-24 US claimed
US-20190002393-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2019-01-03 US claimed
US-10125092-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2018-11-13 US claimed
US-20170275243-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2017-09-28 US claimed
EP-3188760-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2017-07-12 EP claimed
WO-2016037053-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2016-03-10 WO claimed
WO-2024019936-A1 NANOMATERIALS COMPRISING TRIOLS BEAM THERAPEUTICS INC. (US) 2024-01-25 WO disclosed
EP-3188760-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2023-12-06 EP disclosed
EP-4281050-A1 NANOMATERIALS Beam Therapeutics Inc. (US) 2023-11-29 EP disclosed
CN-116761888-A Nanomaterial for the preparation of a nanoparticle 比姆医疗股份有限公司 2023-09-15 CN disclosed
EP-4019506-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2022-06-29 EP disclosed
EP-3083579-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2022-01-26 EP disclosed
WO-2015095340-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2015-06-25 WO disclosed
WO-2015095346-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2015-06-25 WO disclosed
WO-2015095351-A1 LEPTIN mRNA COMPOSITIONS AND FORMULATIONS NOVARTIS AG (CH) 2015-06-25 WO disclosed
EP-0748310-B1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO SPA (IT) 1999-06-02 EP disclosed
US-5827881-A ADMINISTERING FOR TREATMENT OF VIRAL DISEASES OR AS ANTIINFLAMMATORY AGENTS ITALFARMACO S.P.A. (IT) 1998-10-27 US disclosed
EP-0748310-A1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO S.p.A. (IT) 1996-12-18 EP disclosed
WO-1995023128-A1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO S.P.A. (IT) 1995-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844002-B2 Lipids and lipid compositions for the delivery of active agents LRAT, LIPA, LPAR1 CHRM2 3201/4885CHRM4 3566/4885CHRM1 3713/4885
US-20170275243-A1 Lipids and Lipid Compositions for the Delivery of Active Agents LRAT, LPAR4, LPAR1 CHRM2 3281/4885CHRM4 3595/4885CHRM1 3791/4885
US-10125092-B2 Lipids and lipid compositions for the delivery of active agents LRAT, LPAR4, LPAR1 CHRM2 3281/4885CHRM4 3595/4885CHRM1 3791/4885
US-20190002393-A1 Lipids and Lipid Compositions for the Delivery of Active Agents LRAT, LIPA, LPAR1 CHRM2 3201/4885CHRM4 3566/4885CHRM1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.